Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
- Autores
- Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; Haab, Gabriela Acosta; Bardach, Ariel Esteban
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; Argentina
Fil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina - Materia
-
INMUNOHISTOCHEMISTRY
MALIGNANT TUMORS
HISTOLOGY
UTERINE CANCER - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/184501
Ver los metadatos del registro completo
id |
CONICETDig_7241f4622ac5c338c2038710b865d44c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/184501 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysisItkin, BorisGarcia, AgustinStraminsky, SamantaAdelchanow, Eduardo DanielPereyra, MatiasHaab, Gabriela AcostaBardach, Ariel EstebanINMUNOHISTOCHEMISTRYMALIGNANT TUMORSHISTOLOGYUTERINE CANCERhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; ArgentinaFil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaPublic Library of Science2021-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/184501Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-241932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257976info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0257976info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:33:54Zoai:ri.conicet.gov.ar:11336/184501instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:33:54.883CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
title |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
spellingShingle |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis Itkin, Boris INMUNOHISTOCHEMISTRY MALIGNANT TUMORS HISTOLOGY UTERINE CANCER |
title_short |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
title_full |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
title_fullStr |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
title_full_unstemmed |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
title_sort |
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis |
dc.creator.none.fl_str_mv |
Itkin, Boris Garcia, Agustin Straminsky, Samanta Adelchanow, Eduardo Daniel Pereyra, Matias Haab, Gabriela Acosta Bardach, Ariel Esteban |
author |
Itkin, Boris |
author_facet |
Itkin, Boris Garcia, Agustin Straminsky, Samanta Adelchanow, Eduardo Daniel Pereyra, Matias Haab, Gabriela Acosta Bardach, Ariel Esteban |
author_role |
author |
author2 |
Garcia, Agustin Straminsky, Samanta Adelchanow, Eduardo Daniel Pereyra, Matias Haab, Gabriela Acosta Bardach, Ariel Esteban |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
INMUNOHISTOCHEMISTRY MALIGNANT TUMORS HISTOLOGY UTERINE CANCER |
topic |
INMUNOHISTOCHEMISTRY MALIGNANT TUMORS HISTOLOGY UTERINE CANCER |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues. Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina Fil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires; Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina Fil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; Argentina Fil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina Fil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires; Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina |
description |
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/184501 Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-24 1932-6203 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/184501 |
identifier_str_mv |
Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-24 1932-6203 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257976 info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0257976 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Public Library of Science |
publisher.none.fl_str_mv |
Public Library of Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613045857288192 |
score |
13.070432 |